Vazquez Manuel Sanz

BRAINco Biopharma SL develops and produces diagnosis and treatment for neurological and psychiatric diseases. It develops drugs directed against therapeutic targets and diagnostic biochips, prognosis, and prediction of individual response to drug treatment. The company was founded by Laureano Simon Buela in 2008 and is headquartered in Bilbao, Spain.

Progenika Biopharma SA engages in the design and development of molecular biology testing solutions. The firm offers ID Core Control, ID RHD, ID Core, SeqPro Lipo IS, and A1AT genotyping test. The company was founded in 2000 and is headquartered in Derio, Spain.

Cámara Oficial de Comercio Industria y Navegación de Gipuzkoa operates business associations and provides business consulting services. Its service portfolio includes planning, legal, and business development. The company is headquartered in San Sebastian, Spain.

StemTek Therapeutics SL is a biopharmaceutical company. It provides research services portfolio in drug development for cancer treatment. The company offers screening and custom services. StemTek Therapeutics was founded by Angel García Martín, Olatz Leis Esnaola, and Gabriel Inclan Blanco in 2013 and is headquartered in Derio, Spain.

The Chamber of Commerce of Gipuzkoa is a business organization that serves as a platform for companies to connect and collaborate. The organization is based in Donostia, Spain.

Patia Europe SL is a public health company based in Donostia-San Sebastián, Spain. The Spanish company integrates genetic, metabolomic, and digital tools to facilitate the prevention and control of type 2 diabetes. Patia's team has extensive experience in the fields of molecular biology and genomic medicine, complemented by top-level alliances with prestigious research centers in and the Americas to make the most advanced genomic and technological tools available to the population in the most accessible way. Patia offers a laboratory test called Diabetespredict™, which provides an evaluation of high sensitivity and specificity of the genetic predisposition to develop type 2 diabetes (DT2). Additionally, it offers personalized recommendations based on the patient's genetics. The test has been developed in collaboration with scientists and endocrinologists from the Hospital General de. Patia also works to reduce the effects of the COVID-19 pandemic on people with diabetes.

Nelum Corp. operates as a clinical stage biopharmaceutical firm. Its focus areas include cancer and fibrosis. The company is headquartered in Durham, NC.